Management of Down Syndrome–Associated Leukemias
Authors:
- 1 September 2023
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 9 (9) , 1283-1290
Abstract
Importance: Down syndrome (DS), caused by an extra copy of material from chromosome 21, is one of the most common genetic conditions. The increased risk of acute leukemia in DS (DS-AL) has been recognized for decades, consisting of an approximately 150-fold higher risk of acute myeloid leukemia (AML) before age 4 years, and a 10- to 20-fold higher risk of acute lymphoblastic leukemia (ALL), compared with children without DS.Observations: A recent National Institutes of Health-sponsored conference, ImpacT21, reviewed research and clinical trials in children, adolescents, and young adults (AYAs) with DS-AL and are presented herein, including presentation and treatment, clinical trial design, and ethical considerations for this unique population. Between 10% to 30% of infants with DS are diagnosed with transient abnormal myelopoiesis (TAM), which spontaneously regresses. After a latency period of up to 4 years, 20% to 30% develop myeloid leukemia associated with DS (ML-DS). Recent studies have characterized somatic mutations associated with progression from TAM to ML-DS, but predicting which patients will progress to ML-DS remains elusive. Clinical trials for DS-AL have aimed to reduce treatment-related mortality (TRM) and improve survival. Children with ML-DS have better outcomes compared with non-DS AML, but outcomes remain dismal in relapse. In contrast, patients with DS-ALL have inferior outcomes compared with those without DS, due to both higher TRM and relapse. Management of relapsed leukemia poses unique challenges owing to disease biology and increased vulnerability to toxic effects. Late effects in survivors of DS-AL are an important area in need of further study because they may demonstrate unique patterns in the setting of chronic medical conditions associated with DS.Conclusions and Relevance: Optimal management of DS-AL requires specific molecular testing, meticulous supportive care, and tailored therapy to reduce TRM while optimizing survival. There is no standard approach to treatment of relapsed disease. Future work should include identification of biomarkers predictive of toxic effects; enhanced clinical and scientific collaborations; promotion of access to novel agents through innovative clinical trial design; and dedicated studies of late effects of treatment.Keywords
This publication has 62 references indexed in Scilit:
- Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21Proceedings of the National Academy of Sciences, 2012
- Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971Blood, 2011
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemiaNature Genetics, 2009
- Trisomy 21 enhances human fetal erythro-megakaryocytic developmentBlood, 2008
- Treatment and prognostic impact of transient leukemia in neonates with Down syndromeBlood, 2008
- Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG studyBlood, 2008
- Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study GroupJournal of Clinical Oncology, 2007
- Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar BlastsKlinische Padiatrie, 2005
- GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndromeBlood, 2003
- Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesisBlood, 2003